Collaborative Programs

Inhibikase’s business model is two-pronged: Demonstrating clinical proof-of-concept in target populations while simultaneously developing first-in-class and best-in-class medications. The Company intends to commercialize its novel medications, either alone or in partnership, to achieve the best outcome for patients on the shortest timescale possible.

In meeting our primary commitment to patients with diseases of the central nervous system that have little to no treatment options, we collaborate with academic research teams and other third parties to drive our discovery efforts and advance the product candidates in our pipeline.

The Company currently has ongoing collaborations with The Johns Hopkins University; University of Birmingham, Alabama; Louisiana State University School of Medicine, Shreveport; University of California, San Francisco; the M. D. Anderson Cancer Center; and Memorial Sloan-Kettering Cancer Center.

Back to Top